B细胞受体信号通路抑制剂在淋巴瘤中的应用及耐药机制研究进展:第57届美国血液学会年会报道

摘要

近年来,B细胞受体(BCR)信号通路抑制剂在复发、难治B细胞非霍奇金淋巴瘤(B-NHL)患者治疗中取得了振奋人心的疗效,大量BCR信号通路抑制剂单用或联合其他传统化疗药物、免疫调节剂、单克隆抗体及其他激酶抑制剂的临床研究正在如火如荼地开展.此外,已有研究发现了BCR信号通路抑制剂耐药的情况,其发生机制及如何克服耐药已引起关注.文章结合2015年第57届美国血液学会(ASH)年会报道的BCR信号通路抑制剂单药及联合用药的最新研究进展及其耐药机制的相关研究进行介绍,以期为临床治疗提供帮助.%With the recent success of B-cell receptor (BCR) signaling pathway inhibitor in the treatment of patients with relapsed or refractory non-Hodgkin lymphoma (NHL), a number of new agents targeting the BCR signaling pathway are in a clinical research stage. In addition, multiple trials combining these agents with conventional cytotoxic chemotherapy, immunomodulatory agents, monoclonal antibodies, or other kinase inhibitors are underway. Studies have also found the drug resistance of BCR signaling pathway inhibitors, drawing attention of the mechanism and the way to overcome the drug resistance. Combined with the research progress reported in 57th American Society of Hematology (ASH) annual meeting, this article summarized the recent progress of BCR signaling pathway inhibitors and their resistance mechanism to provide new information on clinical therapy.